Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosapride vs Metoclopramide for Enteral Feeding Intolerance
NCT06826443Phase 3Not yet recruiting
- Sponsor
- Ain Shams University
- Start
- Feb 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of mosapride in enteral feeding intolerance (EFI) (2 arms), sponsored by Ain Shams University. Primary endpoint: Gastric Residual Volume. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
mosapride
03
Conditions
enteral feeding intolerance (EFI)
Beyond the preview
Go deeper on NCT06826443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06826443.